Shuchi Gulati
A5050155318- Head and Neck Cancer Studies
- Renal cell carcinoma treatment
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Ferroptosis and cancer prognosis
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Lung Cancer Research Studies
- Renal and related cancers
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Head and Neck Surgical Oncology
- COVID-19 Clinical Research Studies
- CAR-T cell therapy research
- Venous Thromboembolism Diagnosis and Management
- Pancreatic and Hepatic Oncology Research
- Virus-based gene therapy research
- Economic and Financial Impacts of Cancer
- Bladder and Urothelial Cancer Treatments
- Trace Elements in Health
- Metabolism, Diabetes, and Cancer
- Healthcare cost, quality, practices
- Prostate Cancer Treatment and Research
University of California, Davis
2022-2025
UC Davis Comprehensive Cancer Center
2022-2025
University of Cincinnati Medical Center
2015-2024
UC Davis Health System
2024
University of Cincinnati
2012-2023
University of California Davis Medical Center
2022
Stamford Hospital
2020
Reading Hospital
2009-2014
All India Institute of Medical Sciences Bhopal
2006
All India Institute of Medical Sciences Raipur
2006
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort patients and 2019 (COVID-19) reported to the COVID-19 Cancer Consortium (CCC19) identify prognostic clinical factors, including laboratory measurements anticancer therapies. active or historical laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March 18 November 2020 were included. The primary outcome was severity measured...
Abstract Purpose: Patients with resected, local–regionally advanced, head and neck squamous cell carcinoma (HNSCC) have a one-year disease-free survival (DFS) rate of 65%–69% despite adjuvant (chemo)radiotherapy. Neoadjuvant PD-1 immune-checkpoint blockade (ICB) has demonstrated clinical activity, but biomarkers response effect on remain unclear. Methods: Eligible patients had resectable the oral cavity, larynx, hypopharynx, or oropharynx (p16-negative) stage T3-T4 and/or two more nodal...
Metformin slows tumor growth and progression in vitro, combination with chemoradiotherapy, resulted high overall survival patients head neck cancer squamous cell carcinoma (HNSCC) our phase 1 clinical trial (NCT02325401). is also postulated to activate an antitumor immune response. Here, we investigate immunologic effects of metformin on natural killer (NK) T cells, including results from two I open-label studies HNSCC treated (NCT02325401, NCT02083692).Peripheral blood was collected before...
Importance Cytokine storm due to COVID-19 can cause high morbidity and mortality may be more common in patients with cancer treated immunotherapy (IO) immune system activation. Objective To determine the association of baseline immunosuppression and/or IO-based therapies severity cytokine cancer. Design, Setting, Participants This registry-based retrospective cohort study included 12 046 reported Cancer Consortium (CCC19) registry from March 2020 May 2022. The CCC19 is a centralized...
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. Mesenchymal-epithelial transition (MET) signaling pathway plays a role pathogenesis of selected patients with...
Given the upstream location of HIF-2␣ in VHL-HIF-VEGF pathway and its role renal carcinogenesis, has recently become a therapeutic target cell carcinoma (RCC) with drugs such as belzutifan.Belzutifan received FDA approval for patients VHL-associated RCC based on phase 2 clinical trial [1].In LITESPARK-001 1 dose-escalation study that included 55 previously treated advanced RCC, no dose-limiting toxicities occurred at doses up to 160 mg once daily, maximum tolerated dose was not reached...
Molecular profiling of clear cell renal carcinoma (ccRCC) tumors patients in a clinical trial has identified distinct transcriptomic signatures with predictive value, yet data non-clear variants (nccRCC) are lacking. We examined the transcriptional profiles RCC representing key molecular pathways, from multi-institutional, real-world patient cohort, including ccRCC and centrally reviewed nccRCC samples. had increased angiogenesis signature scores compared heterogeneous group tumors, while...
<h3>Importance</h3> Androgen deprivation therapy (ADT) has been theorized to decrease the severity of SARS-CoV-2 infection in patients with prostate cancer owing a potential tissue-based expression coreceptor transmembrane protease, serine 2 (TMPRSS2). <h3>Objective</h3> To examine whether ADT is associated decreased rate 30-day mortality from among cancer. <h3>Design, Setting, and Participants</h3> This cohort study analyzed patient data recorded COVID-19 Cancer Consortium registry between...
<p>Bulk RNA and spatial transcriptomics analysis of ccRCC.</p>
<p>Characterization of subpopulations cancer cells identified by scRNA-seq.</p>
<p>Expression of SLC25A40 glutathione transporter in RCC cells.</p>
<div>Abstract<p>Copper (Cu) is a cofactor of cytochrome c oxidase (CuCOX), indispensable for aerobic mitochondrial respiration. This study reveals that advanced clear cell renal carcinomas (ccRCC) accumulate Cu, allocating it to CuCOX. Using range orthogonal approaches, including metabolomics, lipidomics, isotope-labeled glucose and glutamine flux analysis, transcriptomics across tumor samples, lines, xenografts, patient-derived xenograft models, combined with genetic...
<p>Glucose metabolism in CuHi and CuLo cells.</p>
<p>Cu regulates metabolism and CuCOX is necessary for Cu-induced tumor growth.</p>
<p>Accumulation of Cu and its allocation to CuCOX correlates with the progression ccRCC drives tumor growth.</p>